On Tuesday, TG Therapeutics Inc (NASDAQ: TGTX) opened lower -0.50% from the last session, before settling in for the closing price of $14.07. Price fluctuations for TGTX have ranged from $6.46 to $35.67 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 2506.46%. Company’s average yearly earnings per share was noted -261.11% at the time writing. With a float of $139.66 million, this company’s outstanding shares have now reached $151.42 million.
Considering the fact that the conglomerate employs 264 people, you should pay attention to its efficiency factor.
TG Therapeutics Inc (TGTX) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of TG Therapeutics Inc is 9.56%, while institutional ownership is 58.82%. The most recent insider transaction that took place on Mar 13 ’24, was worth 79,675. In this transaction Director of this company sold 5,000 shares at a rate of $15.94, taking the stock ownership to the 108,878 shares. Before that another transaction happened on Mar 12 ’24, when Company’s Director sold 22,000 for $15.97, making the entire transaction worth $351,340. This insider now owns 215,229 shares in total.
TG Therapeutics Inc (TGTX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 14.00 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -261.11% per share during the next fiscal year.
TG Therapeutics Inc (NASDAQ: TGTX) Trading Performance Indicators
Check out the current performance indicators for TG Therapeutics Inc (TGTX). In the past quarter, the stock posted a quick ratio of 5.18. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.01, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach 0.45 in one year’s time.
Technical Analysis of TG Therapeutics Inc (TGTX)
Compared to the last year’s volume of 4.22 million, its volume of 2.6 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 14.24%. Additionally, its Average True Range was 0.66.
During the past 100 days, TG Therapeutics Inc’s (TGTX) raw stochastic average was set at 16.79%, which indicates a significant increase from 12.71% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 29.11% in the past 14 days, which was lower than the 74.36% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.19, while its 200-day Moving Average is $13.91. Nevertheless, the first resistance level for the watch stands at $14.19 in the near term. At $14.38, the stock is likely to face the second major resistance level. The third major resistance level sits at $14.60. If the price goes on to break the first support level at $13.79, it is likely to go to the next support level at $13.57. Should the price break the second support level, the third support level stands at $13.38.
TG Therapeutics Inc (NASDAQ: TGTX) Key Stats
There are currently 154,421K shares outstanding in the company with a market cap of 2.16 billion. Presently, the company’s annual sales total 233,660 K according to its annual income of 12,670 K. Last quarter, the company’s sales amounted to 43,970 K and its income totaled -14,420 K.
